Tag Archives: IND

July, 2017

June, 2017

April, 2017

March, 2017

February, 2017

June, 2016

February, 2016

December, 2015

  • 16 December

    FDA Lifts IND Clinical Hold for Three of Advaxis’ Product Candidates

    PRINCETON, N.J., Dec. 16, 2015 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac …